Literature DB >> 28217972

Clinical outcome of partial cystectomy for transitional cell carcinoma of the canine bladder.

S J Marvel1, B Séguin1,2, D D Dailey1, D H Thamm1,2.   

Abstract

Canine transitional cell carcinoma (TCC) of the bladder has historically been treated with a combination of chemotherapy, cyclooxygenase inhibitors and radiation therapy. While surgery has been used to treat TCC of the bladder, its efficacy has yet to be established. Thirty-seven client owned dogs that underwent partial cystectomy +/- various nonsurgical treatments for TCC were retrospectively evaluated. The overall median progression-free interval (PFI) was 235 days and the median survival time (ST) was 348 days. Prognostic factors identified on univariate analysis significant for ST were age, tumor location, full thickness excision and frequency of piroxicam administration. Prognostic factors significant for PFI were full thickness excision and frequency of piroxicam administration. The median ST with partial cystectomy and daily piroxicam therapy, with or without chemotherapy, was 772 days. Dogs with non-trigonal bladder TCC treated with full thickness partial cystectomy and daily piroxicam (+/- chemotherapy) may have improved outcome compared to dogs treated with medical therapy.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  bladder; cystectomy; dog; surgery; transitional cell carcinoma

Mesh:

Substances:

Year:  2017        PMID: 28217972     DOI: 10.1111/vco.12286

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  9 in total

1.  Clinical outcomes of dogs with transitional cell carcinoma receiving medical therapy, with and without partial cystectomy.

Authors:  Marcus L Bradbury; Christine M Mullin; Shaban D Gillian; Chick Weisse; Philip J Bergman; Michelle A Morges; Lauren R May; David M Vail; Craig A Clifford
Journal:  Can Vet J       Date:  2021-02       Impact factor: 1.008

2.  Use of a bipolar sealing device to seal partial cystectomy with and without augmentation with a single-layer simple continuous suture pattern in an ex vivo canine model.

Authors:  Valery F Scharf; Milan Milovancev; Katy L Townsend; Jennifer A Luff
Journal:  Vet Surg       Date:  2020-05-09       Impact factor: 1.495

3.  In-vitro effects of taurolidine alone and in combination with mitoxantrone and/or piroxicam on canine transitional cell carcinoma.

Authors:  Brittney Byer; Lisa J Schlein; Barbara Rose; Bernard Séguin
Journal:  Can J Vet Res       Date:  2020-04       Impact factor: 1.310

4.  Presumptive malignant transformation of chronic polypoid cystitis into an apical transitional cell carcinoma without BRAF mutation in a young female dog.

Authors:  Emmanuelle Marie Butty; Shelley Hahn; Mary Anna Labato
Journal:  J Vet Intern Med       Date:  2021-03-19       Impact factor: 3.333

5.  Lower urinary tract transitional cell carcinoma in cats: Clinical findings, treatments, and outcomes in 118 cases.

Authors:  Maureen A Griffin; William T N Culp; Michelle A Giuffrida; Peter Ellis; Joanne Tuohy; James A Perry; Allison Gedney; Cassie N Lux; Milan Milovancev; Mandy L Wallace; Jonathan Hash; Kyle Mathews; Julius M Liptak; Laura E Selmic; Ameet Singh; Carrie A Palm; Ingrid M Balsa; Philipp D Mayhew; Michele A Steffey; Robert B Rebhun; Jenna H Burton; Michael S Kent
Journal:  J Vet Intern Med       Date:  2019-11-13       Impact factor: 3.333

6.  Treatment of genitourinary carcinoma in dogs using nonsteroidal anti-inflammatory drugs, mitoxantrone, and radiation therapy: A retrospective study.

Authors:  Benoit Clerc-Renaud; Tracy L Gieger; Susan M LaRue; Michael W Nolan
Journal:  J Vet Intern Med       Date:  2021-02-26       Impact factor: 3.333

7.  Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs.

Authors:  Shingo Maeda; Kosei Sakai; Kenjiro Kaji; Aki Iio; Maho Nakazawa; Tomoki Motegi; Tomohiro Yonezawa; Yasuyuki Momoi
Journal:  Sci Rep       Date:  2022-01-13       Impact factor: 4.379

8.  Lymphatic invasion is a significant indicator of poor patient outcome in canine bladder urothelial carcinoma.

Authors:  Verônica M Govoni; Claudio Pigoli; Felipe Augusto R Sueiro; Fernanda Zuliani; Thayná O da Silva; Juliany G Quitzan; Renee Laufer-Amorim; Valeria Grieco; Carlos Eduardo Fonseca-Alves
Journal:  Open Vet J       Date:  2021-10-04

9.  Ablation of Red Stable Transfected Claudin Expressing Canine Prostate Adenocarcinoma and Transitional Cell Carcinoma Cell Lines by C-CPE Gold-Nanoparticle-Mediated Laser Intervention.

Authors:  Suhayla Alnajjar; Ingo Nolte; Annegret Becker; Jan Torben Schille; Nares Trakooljul; Marcus Frank; Anaclet Ngezahayo; Hugo Murua Escobar
Journal:  Int J Mol Sci       Date:  2021-11-13       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.